Pars Capital Partners, LLC
Pars Capital Partners, LLC provides M&A advisory, recapitalization, capital-formation, growth-equity, management-buyout, and management-advisory services. Its public materials describe a confidential process involving valuation, buyer outreach, negotiation and closing support, due diligence, underwriting, and virtual data rooms.
What stands out about Pars Capital Partners, LLC
Pars Capital Partners publicly presents an exclusive focus on global clinical-trial infrastructure and pharmaceutical outsourcing, particularly CRO and CDMO companies. It also states that it buys, sells, and invests in CRO and CDMO organizations for its own account and for strategic and financial clients.[1][2][3][4][5]
What does Pars Capital Partners, LLC do?
Pars Capital Partners, LLC identifies itself as a pure-play independent investment banking advisory and investment firm dedicated exclusively to the global clinical-trial infrastructure and pharmaceutical-outsourcing markets. Its listed headquarters address is 8816 Orchard Ave, Brooklyn, Ohio 44144.[1][2]
The firm publicly lists sell-side and buy-side mergers and acquisitions, minority and majority equity recapitalizations, equity and debt capital formation, growth-equity financing, management buyouts, and management advisory.
Its public process descriptions also include valuation and positioning, targeted buyer outreach, negotiation and closing support, due diligence, financial underwriting, auditing, and coordination through institutional-grade virtual data rooms.[1][2][3]
Owners comparing advisory firms can also review Auxo’s M&A advisor vs. business broker vs. investment bank comparison, advisor-selection guide, and sell-side advisor evaluation framework.
What should a business owner evaluate before hiring Pars Capital Partners, LLC?
Owners considering Pars Capital Partners should evaluate the firm’s stated CRO and CDMO specialization, confidential M&A process, valuation and underwriting capabilities, buyer outreach, financial-sponsor relationships, and stated investment activities. The firm publicly states that it has more than 1,400 established proprietary relationships with life-sciences, CRO, and CDMO executives and equity stakeholders and more than 150 vetted financial sponsors.
Because the firm also states that it buys, sells, and invests in CRO and CDMO organizations for its own account and for clients, an owner should clarify potential conflicts, the legal entity providing services, applicable current registrations, completed transaction experience, comparable transaction scope, buyer coverage, and engagement terms.[1][3][4]
Can Pars Capital Partners provide at least three completed CRO, CDMO, or related transactions, including dates, transaction type, size range, buyer category, and the firm's role
Can the firm provide seller references and describe its experience with businesses comparable to the owner's in sector and transaction scope
Could Pars Capital Partners or an affiliate invest for its own account or represent a financial sponsor in a potential transaction, and how would related conflicts be handled
What size transactions and clients does Pars Capital Partners, LLC focus on?
Pars Capital Partners states that its focus is the global clinical-trial infrastructure and pharmaceutical-outsourcing markets. It identifies contract research organizations and contract development and manufacturing organizations as the subject of its activities.[3][4]
The official Insights page presents the first edition of a quarterly Life Sciences Outsourcing Capital Formation & M&A Digest as in preparation and does not identify completed transactions, sold assets, or dated deal examples.[5]
The firm’s stated transaction work includes sell-side and buy-side M&A, minority and majority equity recapitalizations, equity and debt capital formation, growth-equity financing, management buyouts, and management advisory.
The Services page also states that Pars Capital Partners buys, sells, and invests in CRO and CDMO organizations for its own account and for strategic and financial clients.[3]
What does Pars Capital Partners, LLC publicly disclose about fees, process and engagement terms?
The official Services page does not state minimum revenue, EBITDA, enterprise-value, transaction-size, or client-size criteria. That page also does not publish fee percentages, retainer amounts, expense terms, exclusivity provisions, termination provisions, or tail provisions.
The official Insights page does not identify completed transactions, sold assets, or dated deal examples. The official About page describes historical FINRA and SEC broker registration for the Managing Partner but does not identify a current firm-level broker-dealer or investment-adviser registration.[3][4][5]
Pars Capital Partners identifies itself as Pars Capital Partners, LLC and as an independent investment banking advisory and investment firm. The official About page describes the Managing Partner’s historical FINRA and SEC broker-registration experience at institutional broker-dealers including Morgan Stanley, Merrill Lynch Bank of America, and BrokerBank Securities.
The official About page does not identify a current firm-level broker-dealer or investment-adviser registration. The Managing Partner’s historical registration background should not be treated as a current firm-level registration determination.[4]
Pars Capital Partners describes a confidential process involving initial dialogue, a mutual NDA, valuation and positioning, targeted buyer outreach, negotiation and closing support, and institutional-grade virtual data rooms for due diligence, financial underwriting, and auditing.
The official Contact page invites owners to request a confidential assessment of a life-sciences business based on current market conditions and to identify a preferred transaction type.[1][2]
Questions to ask before hiring Pars Capital Partners, LLC
Can Pars Capital Partners provide at least three completed CRO, CDMO, or related transactions, including dates, transaction type, size range, buyer category, and the firm's role?
Can the firm provide seller references and describe its experience with businesses comparable to the owner's in sector and transaction scope?
Could Pars Capital Partners or an affiliate invest for its own account or represent a financial sponsor in a potential transaction, and how would related conflicts be handled?
What written fee, retainer, expense, exclusivity, termination, and tail provisions would apply to the engagement?
Which legal entity would provide the advisory services, and what current broker-dealer, investment-adviser, or other regulatory registrations apply to that entity?
What criteria does the firm use to select and prioritize prospective buyers?
Sources & research notes
- Official website / firm overview
- Official website / firm overview
- Services / capabilities
- Industry / market focus
- Public disclosure information
How this profile was researched
Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.
Independent research profile
This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.
Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.
Broker-dealer and securities disclosure
Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.
Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.
Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.
Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.
